Reference Document

The report describes Poxel's 2018 expansion of its metabolic-disease portfolio through the Roivant partnership and acquisition of PXL065, alongside continued Phase III development of Imeglimin and advancement of PXL770 for NASH. It reports more than 1,100 patients enrolled in the TIMES Phase III program and revenue of €74.6 million for 2018. The non-financial section covers workforce, health and safety, training, equality, environmental impacts, travel-related greenhouse gas emissions, and supplier practices.